In 1999, the UK was the first country to introduce the meningococcal serogroup C conjugate (MCC) vaccine into the childhood immunization schedule together with a catch-up to 18 years of age. In September 2006, a booster dose of (MCC) and Haemophilus influenzae type b (Hib) conjugate vaccine was introduced in the second year of life in England and Wales in the form of a combined vaccine, Menitorix. At the time, no data were available on whether Menitorix could be given together with MMR and Prevenar (PCV7) or on antibody persistence following the booster.
Results of a study where children either received Menitorix at 12 to 14 months of age followed by Prevenar and MMR one month later or all three vaccines at the same visit will be presented. Antibody persistence to MCC and Hib was followed at 1, 2, 12 and 24 months post-booster. Results reveal that no adverse consequences were observed for either immunogenicity or reactogenicity when Menitorix was administered either separately or together with Prevenar and MMR.
For MCC, depending on primary MCC vaccine used, 95 to 100% of children were protected 1 month following the Menitorix booster with the greatest magnitude of response seen for those primed with NeisVac-C (MCC-TT). MCC antibody persistence following the booster dose showed the same kinetics as following the primary MCC series. For MCC, two years post-booster, 27% to 46% of children remained protected, depending on primary MCC. Studies are now underway examining the possibility of a single primary dose of MCC at 3 months of age with a booster in the second year of life.
Presenter: Ray Borrow
Prof. Ray Borrow is Head of the Vaccine Evaluation Unit at the Health Protection Agency (HPA) North West, Manchester, UK, where he is responsible for the evaluation of serological responses to various bacterial and viral vaccines with a special interest in meningococcal and pneumococcal vaccines. He is also Deputy Head of the HPA Meningococcal Reference Unit for England and Wales. He gained his PhD in 1994, MRCPath in 2003 and FRCPath in 2008. He became a Professor of Vaccine Preventable Diseases at the University of Manchester in 2009. His scientific findings resulted in over 170 peer reviewed published papers. He serves as a member of the Department of Health’s Joint Committee of Vaccination and Immunisation (JCVI) and frequently advises WHO and companies on both meningococcal and pneumococcal vaccines. He sits on the medical-scientific advisory panel for the Meningitis Trust, Meningitis Research Foundation and Meningitis UK.
Public Health Ontario is committed to complying with the Accessibility for Ontarians with Disabilities Act (AODA). If you require accommodations to participate in this event, please contact 647-260-7100 or firstname.lastname@example.org.